IL148946A0 - Altering gene expression with ssdna produced in vivo - Google Patents

Altering gene expression with ssdna produced in vivo

Info

Publication number
IL148946A0
IL148946A0 IL14894600A IL14894600A IL148946A0 IL 148946 A0 IL148946 A0 IL 148946A0 IL 14894600 A IL14894600 A IL 14894600A IL 14894600 A IL14894600 A IL 14894600A IL 148946 A0 IL148946 A0 IL 148946A0
Authority
IL
Israel
Prior art keywords
vivo
gene expression
altering gene
ssdna produced
ssdna
Prior art date
Application number
IL14894600A
Original Assignee
Cytogenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytogenix Inc filed Critical Cytogenix Inc
Publication of IL148946A0 publication Critical patent/IL148946A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
IL14894600A 1999-10-04 2000-10-04 Altering gene expression with ssdna produced in vivo IL148946A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41156899A 1999-10-04 1999-10-04
US51470700A 2000-02-28 2000-02-28
PCT/US2000/027381 WO2001025419A1 (en) 1999-10-04 2000-10-04 ALTERING GENE EXPRESSION WITH ssDNA PRODUCED IN VIVO

Publications (1)

Publication Number Publication Date
IL148946A0 true IL148946A0 (en) 2002-09-12

Family

ID=27021437

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14894600A IL148946A0 (en) 1999-10-04 2000-10-04 Altering gene expression with ssdna produced in vivo

Country Status (11)

Country Link
EP (1) EP1222259A1 (en)
JP (1) JP2003511025A (en)
KR (1) KR20020059608A (en)
CN (1) CN1276083C (en)
AU (1) AU7855300A (en)
BR (1) BR0014814A (en)
CA (1) CA2386246A1 (en)
CR (1) CR6613A (en)
IL (1) IL148946A0 (en)
MX (1) MXPA02003422A (en)
WO (1) WO2001025419A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7419964B2 (en) 1999-09-16 2008-09-02 Cytogenix, Inc. Treatment of HSV-related pathologies using ssDNA
WO2002034951A2 (en) 2000-10-23 2002-05-02 Gen-Probe Incorporated Compositions and methods for detecting human immunodeficiency virus 2 (hiv-2)
CN1620503A (en) * 2001-12-14 2005-05-25 耶鲁大学 Intracellular generation of single-stranded DNA
US20050020526A1 (en) * 2003-06-03 2005-01-27 Cytogenix, Inc. Oligodeoxynucleotide intervention for prevention and treatment of sepsis
BRPI0516118A (en) * 2004-09-28 2008-08-26 Cytogenix Inc antimicrobial single strand oligonucleotides and uses thereof
US8658608B2 (en) 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
CN102154269B (en) * 2011-01-06 2012-05-23 湖南农业大学 Polymerase chain reaction (PCR)-based quick construction method for tandem repetitive sequence and special primer pair and use
JP2019508037A (en) 2016-02-16 2019-03-28 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔ Compositions for enhancing targeted gene editing and methods of use thereof
CN108396043A (en) * 2017-02-06 2018-08-14 中国科学院上海应用物理研究所 A kind of preparation method and applications of the ends 5` phosphorylation single stranded DNA
US20220186250A1 (en) * 2018-11-02 2022-06-16 Nikegen, Llc Recombinant parvoviral vectors and method of making and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000022114A1 (en) * 1998-10-09 2000-04-20 Ingene, Inc. PRODUCTION OF ssDNA $i(IN VIVO)
IL142490A0 (en) * 1998-10-09 2002-03-10 Ingene Inc ENZYMATIC SYNTHESIS OF ssDNA

Also Published As

Publication number Publication date
AU7855300A (en) 2001-05-10
KR20020059608A (en) 2002-07-13
WO2001025419A1 (en) 2001-04-12
JP2003511025A (en) 2003-03-25
CA2386246A1 (en) 2001-04-12
CN1399679A (en) 2003-02-26
EP1222259A1 (en) 2002-07-17
CR6613A (en) 2004-04-21
CN1276083C (en) 2006-09-20
MXPA02003422A (en) 2004-09-10
BR0014814A (en) 2002-09-17

Similar Documents

Publication Publication Date Title
DE60026352D1 (en) Biosensor
EP1182450A4 (en) Biosensor
EP1248834A4 (en) Human embryoid body-derived cells
GB9928968D0 (en) Enzyme
AU2002246580A1 (en) Antisense imaging of gene expression of the brain in vivo
IL148946A0 (en) Altering gene expression with ssdna produced in vivo
HUP0105208A3 (en) Gene therapy-1
IL146332A0 (en) PrP-LIKE GENE
GB9906245D0 (en) Enzyme
AU2001270478A1 (en) Gene expression in biological conditions
AU2153401A (en) Gene expression in biological conditions
AU2001286809A1 (en) Genes expressed in the cell cycle
GB9917564D0 (en) Improvements in refining
GB2349803B (en) Improvements in shelving
EP1215284A4 (en) Tsg-like gene
GB2355348B (en) Improvements in connectors
GB9924634D0 (en) Enzyme
GB9905498D0 (en) Expression
GB9908458D0 (en) Enzyme
GB9914764D0 (en) Improvements in rolling pins
AU2003265907A8 (en) In vivo ssdna expression vectors for altering gene expression
GB9917726D0 (en) Figurines
GB9917919D0 (en) Spinner
GB2353743B (en) Improvements in the manufacture of cases
TW408698U (en) Improved solid tire structure formed in one piece